{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:38:08Z","timestamp":1786711088475,"version":"build-2736575974"},"reference-count":41,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Servier Hellas"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"DOI":"10.1080\/14737167.2026.2718413","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:09:11Z","timestamp":1786532951000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-9829","authenticated-orcid":false,"given":"George","family":"Gourzoulidis","sequence":"first","affiliation":[{"name":"Health Through Evidence GP","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Chotzagiannoglou","sequence":"additional","affiliation":[{"name":"Servier Hellas Pharmaceuticals Ltd","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriani","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"Health Through Evidence GP","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleana","family":"Solakidou","sequence":"additional","affiliation":[{"name":"Servier Hellas Pharmaceuticals Ltd","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Tzanetakos","sequence":"additional","affiliation":[{"name":"Health Through Evidence GP","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13597-z"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142277"},{"key":"e_1_3_5_4_1","unstructured":"Ferlay J Laversanne M Ervik M et al. Global Cancer observatory: cancer Tomorrow (version 1.1). 2024]; Available from Jun 10. Available from: https:\/\/gco.iarc.who.int\/tomorrow\/en\/about#references"},{"key":"e_1_3_5_5_1","unstructured":"Ferlay J Ervik M Lam F et al. Global Cancer observatory: cancer Today (version 1.1). [cited 2024 Jun 10]. Available from: https:\/\/gco.iarc.who.int\/today"},{"key":"e_1_3_5_6_1","unstructured":"Cancer Research UK. Pancreatic cancer incidence statistics. 2021 [cited 2025 Jun 19]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/pancreatic-cancer\/incidence#heading-One"},{"key":"e_1_3_5_7_1","unstructured":"National Cancer Institute. Cancer stat facts: pancreatic cancer. 2020; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"key":"e_1_3_5_8_1","unstructured":"European Commission. Pancreatic cancer burden in EU-27. 2023 [cited 2025 Jun 24]. Available from: https:\/\/ecis.jrc.ec.europa.eu\/sites\/default\/files\/2023-12\/Pancreatic_Cancer_2022_ENG.pdf"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143634"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64068-3"},{"key":"e_1_3_5_11_1","unstructured":"Thomas B Burns J Audette J et al. Clinical development success rates 2006\u20132015. [cited 2025 Jun 18]. Available from: https:\/\/www.bio.org\/sites\/default\/files\/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO %20Biomedtracker %20Amplion%202016.pdf"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164368"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5304516"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104528"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02133-1"},{"key":"e_1_3_5_17_1","unstructured":"European Medicines Agency. Onivyde pegylated liposomal (previously known as onivyde). 2025]; Available from Jun 24. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/onivyde-pegylated-liposomal-previously-known-onivyde"},{"key":"e_1_3_5_18_1","unstructured":"European medicines agency. Onivyde: summary of product characteristics. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/onivyde-pegylated-liposomal-epar-product-information_en.pdf"},{"key":"e_1_3_5_19_1","unstructured":"Hellenic society of medical oncology (HESMO) Therapeutic protocols. 10th Edition. [cited 2025 Jun]. Available from: https:\/\/www.hesmo.gr\/images\/%CE%98%CE%B5%CF%81%CE%B1%CF%80%CE%B5%CF%85%CF%84%CE%B9%CE%BA%CE%B1%CC%81_%CE%A0%CF%81%CF%89%CF%84%CE%BF%CC%81%CE%BA%CE%BF%CE%BB%CE%BB%CE%B1_%CE%95%CE%9F%CE%A0%CE%95-10%CE%B7_%CE%95%CC%81%CE%BA%CE%B4%CE%BF%CF%83%CE%B7.pdf"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4175"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1898322"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.245"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2288249"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.366"},{"key":"e_1_3_5_26_1","unstructured":"Woods B Sideris E Palmer S et al. Partitioned survival analysis for decision modelling in health care: a critical review (TSD 19). 2017 [cited 2017 June 2; 2025 August 5]; Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/partitioned-survival-analysis"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.291"},{"key":"e_1_3_5_28_1","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient level data. 2011 [cited 1 March 2013 5 August 2025]; Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0076"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01552-9"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84"},{"key":"e_1_3_5_33_1","author":"Greek Ministry of Health","year":"2026","unstructured":"Greek Ministry of Health. Drug Price Bull. 2026 [cited 2026 21 July]. https:\/\/www.moh.gov.gr\/","journal-title":"Drug Price Bull"},{"key":"e_1_3_5_34_1","unstructured":"National Organisation for Healthcare Services Provision (EOPYY). 2026 Available from: http:\/\/www.eopyy.gov.gr\/Home\/StartPage?a_HomePage=Index"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0606-1"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2023.02.006"},{"key":"e_1_3_5_37_1","unstructured":"International Monetary Fund. World economic outlook database. 2026; Available from https:\/\/www.imf.org\/en\/publications\/weo\/weo-database\/2025\/april\/weo-report?c=174&s=NGDPPC&sy=2025&ey=2027&ssm=0&scsm=1&ssd=1&scc=1&ssc=1&sic=0&sort=country&ds=.&br=0"},{"issue":"11","key":"e_1_3_5_38_1","first-page":"1086","article-title":"Do value thresholds for oncology drugs differ from nononcology drugs?","volume":"20","author":"Bae YH","year":"2014","unstructured":"Bae YH, Mullins CD. Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Spec Pharm. 2014;20(11):1086\u20131092.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S93760"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1258\/135581904322987535"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03867-2"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-024-00578-5"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2718413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2026.2718413","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2718413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:04:12Z","timestamp":1786709052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2718413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":41,"alternative-id":["10.1080\/14737167.2026.2718413"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2718413","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}